BPC-157: EMA vs. FDA Regulatory Approach

What Is BPC-157 and Why Does Its Regulatory Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a segment of human gastric juice protein. It has shown tissue-protective and wound-healing effects across a wide range of preclinical models, including tendon, ligament, muscle, gut, and vascular injury 1. Despite this breadth of animal data, no regulatory agency has approved it for human therapeutic use.

The regulatory gap matters because thousands of patients in the United States have obtained BPC-157 through compounding pharmacies, often for musculoskeletal injuries or gastrointestinal conditions. Without FDA or EMA approval, there is no standardized label, no required manufacturing consistency testing beyond compounding standards, and no post-market safety surveillance infrastructure comparable to what exists for approved drugs. A 2023 FDA safety communication warned consumers about potential risks of compounded peptide products, including BPC-157, citing the absence of evidence for safety or efficacy in humans.

The FDA's Position on BPC-157

The FDA has been explicit: BPC-157 is not an approved drug product. No New Drug Application (NDA) or Biologics License Application (BLA) has been submitted or approved. The peptide has no FDA-assigned label, no approved dosing, and no sanctioned indication.

BPC-157 reached U.S. patients primarily through Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacies to compound medications from bulk ingredients for individual patients with valid prescriptions. For a bulk substance to be eligible for 503A compounding, it must either appear in the United States Pharmacopeia (USP) or be nominated to and reviewed by the FDA's Pharmacy Compounding Advisory Committee.

In late 2023 and into 2024, the FDA proposed changes to its approach toward peptides used in compounding. The agency's draft guidance on bulk drug substances raised the prospect of removing several peptides, including BPC-157, from the list of substances that 503A pharmacies could compound. The FDA cited two concerns: the lack of human safety data and the absence of a USP monograph establishing identity, strength, quality, and purity standards for BPC-157.

This regulatory tightening arrived amid broader FDA scrutiny of the compounded peptide market, which had grown rapidly alongside semaglutide and tirzepatide shortages. BPC-157 was caught in the same enforcement wave, even though its use case is unrelated to GLP-1 receptor agonism.

The EMA's Framework and Why BPC-157 Falls Outside It

The EMA operates under a fundamentally different regulatory architecture than the FDA, and BPC-157 falls through its gaps in a different way.

For a medicine to reach patients across the European Union, the manufacturer must obtain a marketing authorization. The centralized procedure, managed by the EMA, is mandatory for certain product categories (including biotechnology-derived products) and optional for others. No company has submitted a marketing authorization application for BPC-157 through the centralized, decentralized, or mutual recognition procedures. No EPAR exists. No scientific assessment has been published 2.

The key structural difference: Europe lacks a direct analog to the U.S. 503A compounding pathway. Compounding in EU member states is regulated at the national level, with wide variation in what pharmacies may prepare. Some countries (Germany, for example, under the Arzneimittelgesetz) permit magistral preparations where a physician prescribes an individualized formulation, but these provisions are generally narrower than 503A and were not designed to accommodate novel peptides without pharmacopeial monographs.

The practical result is that BPC-157 in Europe has circulated primarily through gray-market channels: research chemical suppliers, online peptide vendors, and importation from non-EU manufacturers. This places it outside any pharmacovigilance system entirely, meaning adverse events are unlikely to be captured in EudraVigilance or national databases.

Why No Sponsor Has Pursued Approval

The absence of an NDA or marketing authorization application is not accidental. Several structural barriers explain why no pharmaceutical company has moved BPC-157 through the approval pipeline.

First, BPC-157 is a naturally derived peptide sequence that may face patentability challenges. Without strong patent protection, a sponsor investing $500 million to $2 billion in clinical development (the estimated cost of bringing a new molecular entity through Phase III trials and regulatory review, per the Tufts Center for the Study of Drug Development) would face immediate generic competition upon approval 3.

Second, the preclinical literature, while extensive, is concentrated. The majority of published BPC-157 studies originate from a single laboratory led by Predrag Sikiric at the University of Zagreb. A 2021 review noted that independent replication of BPC-157's effects by other research groups remains limited 4. Regulatory agencies, both the FDA and EMA, weight independently replicated findings more heavily in risk-benefit assessments.

Third, BPC-157's proposed mechanism of action spans multiple pathways (nitric oxide system, growth factor modulation, dopaminergic activity), making it difficult to design a focused Phase II program around a single, well-defined primary endpoint. The FDA's guidance on peptide drug development emphasizes the need for a clearly defined mechanism and target indication 5.

Head-to-Head: How the Two Agencies Differ on Peptide Regulation

The FDA and EMA share foundational principles (safety, efficacy, quality) but diverge in mechanics that directly affect substances like BPC-157.

Compounding access. The FDA's 503A framework created a legal, regulated route for patients to access BPC-157 with a prescription. The EMA has no such centralized mechanism. This means U.S. patients had greater (and more visible) access to compounded BPC-157 than European patients, but it also means the FDA bore greater regulatory responsibility to monitor the substance's safety profile in human use.

Pharmacovigilance infrastructure. The FDA's MedWatch system accepts voluntary adverse event reports for compounded products, though reporting rates for compounded drugs are known to be far lower than for approved products. The EMA's EudraVigilance system is designed for authorized medicinal products and does not systematically capture adverse events from unauthorized substances obtained outside the regulated supply chain 6.

Bulk substance evaluation. The FDA has a defined nomination and review process for bulk compounding ingredients, which gave BPC-157 at least a procedural path to evaluated status. The EMA defers this to national pharmacopeias and member state authorities, creating a patchwork with no unified evaluation.

Enforcement posture. The FDA has issued warning letters to companies marketing BPC-157 as a dietary supplement or making unapproved drug claims. In 2022 and 2023, several such warning letters targeted peptide sellers. EMA enforcement of unapproved peptide marketing falls to national competent authorities, and enforcement intensity varies substantially across the 27 member states.

The Safety Question Without Human Trial Data

The absence of controlled human trials leaves a significant gap in BPC-157's safety profile. Animal studies have generally reported favorable tolerability, with Sikiric et al. documenting no observed adverse effects across multiple rodent models even at high doses 1. But rodent tolerability does not predict human safety with sufficient reliability for regulatory purposes.

Specific safety concerns that regulatory scientists have raised include potential effects on angiogenesis. BPC-157 promotes blood vessel formation in animal wound-healing models 7. While beneficial for tissue repair, pro-angiogenic activity carries theoretical risk in patients with occult malignancies, where new blood vessel growth could support tumor progression. This concern is analogous to the one that surrounded vascular endothelial growth factor (VEGF) modulators during their development, and it is the type of risk that only controlled human trials with adequate follow-up can quantify.

The FDA's Pharmacy Compounding Advisory Committee reviewed available BPC-157 data and found insufficient evidence to conclude the substance met safety standards for bulk compounding eligibility. The committee's evaluation noted the absence of human pharmacokinetic data, the lack of dose-response characterization in humans, and the unknown long-term effects of exogenous peptide administration 8.

A 2022 case series published in the Journal of Clinical Medicine described five patients who experienced adverse events after self-administering BPC-157 obtained from online sources, including elevated liver enzymes and injection-site reactions 9. The small sample and uncontrolled sourcing limit the conclusions, but the cases highlight the pharmacovigilance blind spot that exists for unregulated peptides.

What a Path to Approval Would Require

For BPC-157 to move from its current regulatory limbo toward authorized status in either jurisdiction, a sponsor would need to complete several steps.

Under the FDA pathway: file an Investigational New Drug (IND) application with Chemistry, Manufacturing, and Controls (CMC) data establishing peptide identity, purity, and stability; complete Phase I safety and pharmacokinetic studies in healthy volunteers; design and execute Phase II dose-finding trials in a specified indication; run adequate and well-controlled Phase III trials; and submit an NDA with the complete data package. The 505(b)(2) pathway, which permits reliance on published literature for part of the safety or efficacy demonstration, could reduce costs if the FDA accepts existing preclinical publications as partial support. But the gap in human data would still require de novo clinical trials.

Under the EMA pathway: the process is analogous. A marketing authorization application through the centralized procedure would require a full dossier including quality (Module 3), nonclinical (Module 4), and clinical (Module 5) documentation per the Common Technical Document format. The EMA's Committee for Medicinal Products for Human Use (CHMP) would assess the application. Without at least two adequate, well-controlled clinical trials, a positive opinion would be unlikely.

The timeline for either pathway, assuming a sponsor began today, would be 7 to 12 years. That estimate accounts for manufacturing scale-up, clinical trial design, enrollment, data analysis, and regulatory review.

Current Legal Status for Patients and Clinicians

As of May 2026, BPC-157 occupies a narrow and shifting legal space. In the United States, the FDA's proposed restrictions on compounding bulk substances, if finalized, would effectively end 503A pharmacy access. Clinicians who previously prescribed compounded BPC-157 would face potential regulatory liability if they continued to do so after a final rule. Patients who obtained BPC-157 from non-pharmacy sources (research chemical vendors, international suppliers) do so entirely outside the regulated drug supply chain, with no assurance of identity, potency, sterility, or purity.

In Europe, the situation is more fragmented. BPC-157 is not a controlled substance in most member states, but selling it for human therapeutic use without marketing authorization violates EU pharmaceutical law. National enforcement varies. The practical reality is that European patients access BPC-157 through the same unregulated online channels as U.S. patients, but without even the historical overlay of 503A compounding oversight.

The World Anti-Doping Agency (WADA) added BPC-157 to its Prohibited List under the category of peptide hormones, growth factors, and related substances, effective January 2022 10. Athletes subject to WADA testing face sanctions for BPC-157 use regardless of its prescription or compounding status.